Hyperfine, Inc. Reports Third Quarter 2024 Financial Results
Hyperfine (HYPR) reported strong Q3 2024 financial results with record revenues of $3.64 million, up 56% year-over-year. Gross margin improved to 52% from 48% in Q3 2023. The company posted a net loss of $10.33 million ($0.14 per share), compared to $10.76 million ($0.15 per share) in Q3 2023.
Key achievements include CE approval and FDA clearance of 9th generation AI-powered brain imaging software, and significant clinical data presentations for Alzheimer's and stroke applications. Management expects full-year 2024 revenue of $14-14.5 million, representing 27-31% growth, with projected cash burn of $37-40 million.
Hyperfine (HYPR) ha riportato risultati finanziari solidi per il terzo trimestre del 2024, con ricavi record di 3,64 milioni di dollari, in aumento del 56% rispetto all'anno precedente. Il margine lordo è migliorato al 52% rispetto al 48% del terzo trimestre del 2023. L'azienda ha registrato una perdita netta di 10,33 milioni di dollari (0,14 dollari per azione), rispetto a 10,76 milioni di dollari (0,15 dollari per azione) nel terzo trimestre del 2023.
Le principali conquiste includono l'approvazione CE e il rilascio della FDA per il software di imaging cerebrale potenziato dall'IA di nona generazione, e presentazioni significative di dati clinici per applicazioni relative all'Alzheimer e agli ictus. La direzione prevede un fatturato totale per il 2024 compreso tra 14 e 14,5 milioni di dollari, rappresentando una crescita del 27-31%, con un prevedibile consumo di liquidità di 37-40 milioni di dollari.
Hyperfine (HYPR) reportó resultados financieros sólidos durante el tercer trimestre de 2024, con ingresos récord de 3.64 millones de dólares, un aumento del 56% en comparación con el año anterior. El margen bruto mejoró al 52% desde el 48% en el tercer trimestre de 2023. La compañía tuvo una pérdida neta de 10.33 millones de dólares (0.14 dólares por acción), en comparación con 10.76 millones de dólares (0.15 dólares por acción) en el tercer trimestre de 2023.
Los logros clave incluyen la aprobación CE y la autorización de la FDA para un software de imagen cerebral de novena generación impulsado por IA, así como presentaciones clínicas significativas para aplicaciones relacionadas con el Alzheimer y los accidentes cerebrovasculares. La dirección espera ingresos anuales de 2024 de entre 14 y 14.5 millones de dólares, lo que representa un crecimiento del 27-31%, con una quema de efectivo proyectada de 37-40 millones de dólares.
Hyperfine (HYPR)은 2024년 3분기 강력한 재무 결과를 보고했으며, 기록적인 수익 364만 달러를 기록하며 전년 대비 56% 증가했습니다. 총 마진은 2023년 3분기의 48%에서 52%로 개선되었습니다. 회사는 1033만 달러의 순손실을 기록했으며 (주당 0.14달러), 2023년 3분기의 1076만 달러 (주당 0.15달러)와 비교됩니다.
주요 성과로는 9세대 AI 기반 뇌 영상 소프트웨어의 CE 승인 및 FDA 승인, 그리고 알츠하이머 및 뇌졸중 애플리케이션에 대한 중요한 임상 데이터 발표가 포함됩니다. 경영진은 2024년 총 수익이 1400만에서 1450만 달러에 이를 것으로 예상하며, 이는 27-31% 성장에 해당하며 예상 현금 소모는 3700만에서 4000만 달러입니다.
Hyperfine (HYPR) a annoncé de bons résultats financiers pour le troisième trimestre 2024, avec des revenus record de 3,64 millions de dollars, en hausse de 56 % par rapport à l'an dernier. La marge brute a augmenté à 52 % contre 48 % au troisième trimestre 2023. La société a enregistré une perte nette de 10,33 millions de dollars (0,14 dollar par action), contre 10,76 millions de dollars (0,15 dollar par action) au troisième trimestre 2023.
Les réalisations clés comprennent l'approbation CE et l'autorisation de la FDA du logiciel d'imagerie cérébrale alimenté par l'IA de neuvième génération, ainsi que des présentations de données cliniques significatives pour des applications liées à la maladie d'Alzheimer et aux AVC. La direction s'attend à un chiffre d'affaires total pour 2024 compris entre 14 et 14,5 millions de dollars, représentant une croissance de 27 à 31 %, avec une consommation de liquidités projetée de 37 à 40 millions de dollars.
Hyperfine (HYPR) berichtete im dritten Quartal 2024 über starke finanzielle Ergebnisse mit Rekordumsätzen von 3,64 Millionen Dollar, was einem Anstieg von 56 % im Vergleich zum Vorjahr entspricht. Die Bruttomarge verbesserte sich von 48 % auf 52 % im dritten Quartal 2023. Das Unternehmen verzeichnete einen Nettoverlust von 10,33 Millionen Dollar (0,14 Dollar pro Aktie), verglichen mit 10,76 Millionen Dollar (0,15 Dollar pro Aktie) im dritten Quartal 2023.
Zu den wichtigsten Errungenschaften gehören die CE-Zulassung und die FDA-Freigabe der 9. Generation von KI-gestützter Gehirnbildgebungssoftware sowie bedeutende klinische Datenpräsentationen für Anwendungen bei Alzheimer und Schlaganfall. Das Management erwartet für das Gesamtjahr 2024 Umsätze von 14 bis 14,5 Millionen Dollar, was einem Wachstum von 27-31 % entspricht, mit einer voraussichtlichen Liquiditätsverzehr von 37-40 Millionen Dollar.
- Record quarterly revenue of $3.64M, up 56% YoY
- Gross margin improvement to 52% from 48% YoY
- Reduced net loss per share to $0.14 from $0.15 YoY
- Obtained CE approval and FDA clearance for new AI-powered software
- Projected 27-31% revenue growth for full year 2024
- Continued net loss of $10.33M in Q3 2024
- Increased R&D expenses to $5.98M from $5.74M YoY
- Expected significant cash burn of $37-40M for 2024
Insights
Hyperfine's Q3 2024 results demonstrate meaningful progress with
The projected full-year revenue of
The clinical validation progress is noteworthy, particularly in Alzheimer's and stroke detection. The publication in Annals of Neurology and presentations at major conferences demonstrate growing scientific acceptance. The 9th generation AI-powered software upgrade with both FDA clearance and CE approval strengthens the company's competitive position.
The University of Glasgow study showing faster stroke detection compared to conventional MRI represents a significant clinical advantage. These developments suggest increasing clinical utility and market potential for the Swoop® system, though market penetration and widespread adoption rates will be important metrics to monitor.
GUILFORD, Connecticut, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced third quarter 2024 financial results and provided a business update.
“The Hyperfine team delivered yet another strong quarter of financial performance across revenue growth, gross margin expansion, and disciplined cash management while executing against several important priorities in our plans to expand into new sites of care and internationally,” said Maria Sainz, Chief Executive Officer and President of Hyperfine, Inc. “I am increasingly confident in our growth prospects in 2025 and beyond as we execute on our expansion strategy with advancements in image quality and clinical evidence.”
Third Quarter 2024 Financial Results
- Revenues were a record
$3.64 million , up56% , compared to$2.33 million in the third quarter of 2023. - Gross margin was
$1.91 million , compared to$1.12 million in the third quarter of 2023, translating to a gross margin of52% compared to48% in the third quarter of 2023. - Research and development expenses were
$5.98 million , compared to$5.74 million in the third quarter of 2023. - Sales, marketing, general, and administrative expenses were
$6.89 million , compared to$7.14 million in the third quarter of 2023. - Net loss was
$10.33 million , equating to a net loss of$0.14 per share, as compared to a net loss of$10.76 million , or a net loss of$0.15 per share, for the third quarter of 2023.
Recent Achievements and Business Highlights
- Technology Enhancements:
- Obtained CE approval of 9th generation AI-powered brain imaging software with enhanced speed.
- Commenced full rollout of 9th generation AI-powered brain imaging software following FDA clearance in July 2024.
- Alzheimer’s Clinical Data:
- High exposure at three significant Alzheimer’s meetings: Alzheimer’s Association International Conference (AAIC) Philadelphia, AAIC Tokyo, and the Clinical Trials on Alzheimer’s Disease conference with three presentations showcasing the potential value of the Swoop® system in Alzheimer’s patient management.
- Stroke Clinical Data:
- Subset of ACTION PMR (ACuTe Ischemic strOke detectioN with Portable MR) study data from MGH and Yale, published in the August 2024 issue of Annals of Neurology.
- Presentation by Keith Muir, MD, of the University of Glasgow, at European Society of Radiology showcasing the Swoop® systems ability to detect stroke was significantly faster than conventional MRI in the Emergency Room setting.
Nine Months Financial Results
- Revenues were
$10.57 million , up27% , compared to$8.35 million in the nine months ended September 30, 2023. - Gross margin was
$5.07 million , compared to$3.72 million in the nine months ended September 30, 2023, translating to a gross margin percentage of48% in the nine months ended September 30, 2024, compared to a gross margin percentage of45% in the nine months ended September 30, 2023. - Research and development expenses were
$17.51 million , compared to$16.53 million in the nine months ended September 30, 2023. - Sales, marketing, general, and administrative expenses were
$20.13 million , compared to$23.68 million in the nine months ended September 30, 2023. - Net loss was
$30.33 million , equating to a net loss of$0.42 per share, as compared to a net loss of$33.55 million , or a net loss of$0.47 per share, for the nine months ended September 30, 2023.
2024 Financial Guidance
- Management expects revenue for the full year 2024 to be
$14 t o$14.5 million , reflecting year over year growth of27% to31% . - Management expects its cash burn for the full year 2024 to be
$37 t o$40 million .
Conference Call
Hyperfine, Inc. will host a conference call at 1:30 p.m. PT/ 4:30 p.m. ET on Tuesday, November 12, 2024, to discuss its third quarter 2024 financial results and provide a business update. Those interested in listening should register online by visiting https://investors.hyperfine.io/. and clicking on News & Events. Participants are encouraged to register more than 15 minutes before the start of the call. A live and archived audio webcast will be available through the Investors page of Hyperfine, Inc.’s corporate website at https://investors.hyperfine.io/.
About Hyperfine, Inc. and the Swoop® Portable MR Imaging® System
Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of care. The Swoop® system received initial U.S. Food and Drug Administration (FDA) clearance in 2020 as a portable magnetic resonance brain imaging device for producing images that display the internal structure of the head where a full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. The Swoop® system has been approved for brain imaging in several countries, including Canada and Australia, has UKCA certification in the United Kingdom, CE certification in the European Union, and is also available in New Zealand.
The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging and data solutions. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. Traditionally, access to costly, stationary, conventional MRI technology can be inconvenient or not available when needed most. With the portable, ultra-low-field Swoop® system, Hyperfine, Inc. is redefining the neuroimaging workflow by bringing brain imaging to the patient’s bedside. For more information, visit hyperfine.io.
Hyperfine, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the “Company”) may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations about the Company’s financial and operating results, including, the Company’s expected revenue and cash burn for the full year 2024, the Company’s goals and commercial plans, including the Company’s plans to expand internationally and in new sites of care, the Company’s stroke observational clinical study and Alzheimer’s feasibility study, the benefits of the Company’s products and services, progress on improvements and advancements in the Company’s products and services, and the Company’s future performance, including its financial performance, and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company’s product development and commercialization activities, including the degree that the Swoop® system is accepted and used by healthcare professionals; the ability to maintain the listing of the Company’s Class A common stock on the Nasdaq Stock Market LLC; the Company’s ability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the ability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the ability of the Company to identify, in-license or acquire additional technology; the ability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the ability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services and reimbursement for medical procedures conducted using the Company’s products and services; the Company’s ability to successfully complete and generate positive data from the ACTION PMR study and the CARE PMR study; the Company’s ability to generate clinical evidence of the benefits of the Company’s products and services and to progress on product advancements and improvements; the Company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties indicated from time to time in Company’s filings with the Securities and Exchange Commission, including those under “Risk Factors” therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
Investor Contact
Webb Campbell
Gilmartin Group LLC
webb@gilmartinir.com
| HYPERFINE, INC. AND SUBSIDIARIES | ||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
| (in thousands, except share and per share amounts) | ||||||||
| (Unaudited) | ||||||||
| September 30, 2024 | December 31, 2023 | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash and cash equivalents | $ | 45,765 | $ | 75,183 | ||||
| Restricted cash | 219 | 621 | ||||||
| Accounts receivable, less allowance of | 6,800 | 3,189 | ||||||
| Unbilled receivables | 2,264 | 942 | ||||||
| Inventory | 7,044 | 6,582 | ||||||
| Prepaid expenses and other current assets | 2,002 | 2,391 | ||||||
| Total current assets | 64,094 | 88,908 | ||||||
| Property and equipment, net | 3,125 | 2,999 | ||||||
| Other long term assets | 2,167 | 2,292 | ||||||
| Total assets | $ | 69,386 | $ | 94,199 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Accounts payable | $ | 1,404 | $ | 1,214 | ||||
| Deferred grant funding | 219 | 621 | ||||||
| Deferred revenue | 1,413 | 1,453 | ||||||
| Due to related parties | 53 | 61 | ||||||
| Accrued expenses and other current liabilities | 6,870 | 5,419 | ||||||
| Total current liabilities | 9,959 | 8,768 | ||||||
| Long term deferred revenue | 1,105 | 968 | ||||||
| Other noncurrent liabilities | — | 64 | ||||||
| Total liabilities | 11,064 | 9,800 | ||||||
| COMMITMENTS AND CONTINGENCIES | ||||||||
| STOCKHOLDERS' EQUITY | ||||||||
| Class A Common stock, $.0001 par value; 600,000,000 shares authorized; 57,893,458 and 56,840,949 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | 5 | 5 | ||||||
| Class B Common stock, $.0001 par value; 27,000,000 shares authorized; 15,055,288 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | 2 | 2 | ||||||
| Additional paid-in capital | 342,367 | 338,114 | ||||||
| Accumulated deficit | (284,052 | ) | (253,722 | ) | ||||
| Total stockholders' equity | 58,322 | 84,399 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 69,386 | $ | 94,199 | ||||
| HYPERFINE, INC. AND SUBSIDIARIES | ||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | ||||||||||||||||
| (in thousands, except share and per share amounts) | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Sales | ||||||||||||||||
| Device | $ | 3,033 | $ | 1,728 | $ | 8,707 | $ | 6,670 | ||||||||
| Service | 610 | 602 | 1,862 | 1,676 | ||||||||||||
| Total sales | 3,643 | 2,330 | 10,569 | 8,346 | ||||||||||||
| Cost of sales | ||||||||||||||||
| Device | 1,359 | 835 | 4,280 | 3,321 | ||||||||||||
| Service | 376 | 371 | 1,224 | 1,302 | ||||||||||||
| Total cost of sales | 1,735 | 1,206 | 5,504 | 4,623 | ||||||||||||
| Gross margin | 1,908 | 1,124 | 5,065 | 3,723 | ||||||||||||
| Operating Expenses: | ||||||||||||||||
| Research and development | 5,865 | 5,739 | 17,394 | 16,531 | ||||||||||||
| General and administrative | 4,510 | 4,615 | 13,361 | 16,103 | ||||||||||||
| Sales and marketing | 2,496 | 2,529 | 6,769 | 7,575 | ||||||||||||
| Total operating expenses | 12,871 | 12,883 | 37,524 | 40,209 | ||||||||||||
| Loss from operations | (10,963 | ) | (11,759 | ) | (32,459 | ) | (36,486 | ) | ||||||||
| Interest income | 585 | 1,021 | 2,056 | 2,920 | ||||||||||||
| Other income (expense), net | 52 | (19 | ) | 73 | 12 | |||||||||||
| Loss before provision for income taxes | (10,326 | ) | (10,757 | ) | (30,330 | ) | (33,554 | ) | ||||||||
| Provision for income taxes | — | — | — | — | ||||||||||||
| Net loss and comprehensive loss | $ | (10,326 | ) | $ | (10,757 | ) | $ | (30,330 | ) | $ | (33,554 | ) | ||||
| Net loss per common share attributable to common stockholders, basic and diluted | $ | (0.14 | ) | $ | (0.15 | ) | $ | (0.42 | ) | $ | (0.47 | ) | ||||
| Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted | 72,678,622 | 71,464,315 | 72,219,681 | 71,178,769 | ||||||||||||
| HYPERFINE, INC. AND SUBSIDIARIES | ||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
| (in thousands) | ||||||||
| (Unaudited) | ||||||||
| Nine Months Ended September 30, | ||||||||
| 2024 | 2023 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | (30,330 | ) | $ | (33,554 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation | 775 | 791 | ||||||
| Stock-based compensation expense | 3,308 | 3,453 | ||||||
| Loss on disposal of property and equipment, net | 156 | 48 | ||||||
| Other | 6 | 25 | ||||||
| Changes in assets and liabilities: | ||||||||
| Accounts receivable, net | (3,611 | ) | (334 | ) | ||||
| Unbilled receivables | (1,322 | ) | (228 | ) | ||||
| Inventory | (579 | ) | (2,494 | ) | ||||
| Prepaid expenses and other current assets | (324 | ) | 1,010 | |||||
| Due from related parties | — | 48 | ||||||
| Prepaid inventory | 693 | 281 | ||||||
| Other long term assets | (9 | ) | 142 | |||||
| Accounts payable | 193 | 229 | ||||||
| Deferred grant funding | (402 | ) | (196 | ) | ||||
| Deferred revenue | 97 | (364 | ) | |||||
| Due to related parties | (8 | ) | 48 | |||||
| Accrued expenses and other current liabilities | 949 | (776 | ) | |||||
| Operating lease liabilities, net | (2 | ) | — | |||||
| Net cash used in operating activities | (30,410 | ) | (31,871 | ) | ||||
| Cash flows from investing activities: | ||||||||
| Purchases of property and equipment | (375 | ) | (546 | ) | ||||
| Net cash used in investing activities | (375 | ) | (546 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Proceeds from exercise of stock options | 160 | 146 | ||||||
| Proceeds from shares issued under “at-the-market” offering program, net of selling costs | 805 | — | ||||||
| Net cash provided by financing activities | 965 | 146 | ||||||
| Net decrease in cash and cash equivalents and restricted cash | (29,820 | ) | (32,271 | ) | ||||
| Cash, cash equivalents and restricted cash, beginning of period | 75,804 | 118,243 | ||||||
| Cash, cash equivalents and restricted cash, end of period | 45,984 | 85,972 | ||||||
| Reconciliation of cash, cash equivalents, and restricted cash reported in the balance sheets | ||||||||
| Cash and cash equivalents | 45,765 | 85,424 | ||||||
| Restricted cash | 219 | 548 | ||||||
| Total cash, cash equivalents and restricted cash | $ | 45,984 | $ | 85,972 | ||||
| Supplemental disclosure of noncash information: | ||||||||
| Unpaid purchase of property and equipment | $ | 571 | $ | 54 | ||||
FAQ
What was Hyperfine's (HYPR) revenue growth in Q3 2024?
What is Hyperfine's (HYPR) revenue guidance for full-year 2024?
What was Hyperfine's (HYPR) gross margin in Q3 2024?
What regulatory approvals did Hyperfine (HYPR) receive in 2024?
